Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Testing population-based performance measures identifies gaps in juvenile idiopathic arthritis (JIA) care.

Barber CEH, Lix LM, Lacaille D, Marshall DA, Kroeker K, Benseler S, Twilt M, Schmeling H, Barnabe C, Hazlewood GS, Bykerk V, Homik J, Thorne JC, Burt J, Mosher D, Katz S, Shiff NJ.

BMC Health Serv Res. 2019 Aug 14;19(1):572. doi: 10.1186/s12913-019-4379-4.

2.

Anti-NT5c1A Autoantibodies as Biomarkers in Inclusion Body Myositis.

Amlani A, Choi MY, Tarnopolsky M, Brady L, Clarke AE, Garcia-De La Torre I, Mahler M, Schmeling H, Barber CE, Jung M, Fritzler MJ.

Front Immunol. 2019 Apr 9;10:745. doi: 10.3389/fimmu.2019.00745. eCollection 2019.

3.

Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical Trial.

Bharucha KN, Brunner HI, Calvo Penadés I, Nikishina I, Rubio-Pérez N, Oliveira S, Kobusinska K, Schmeling H, Sztajnbok F, Weller-Heinemann F, Zholobova E, Zulian F, Allen R, Chaitow J, Frane J, Wells C, Ruperto N, De Benedetti F; Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group.

J Rheumatol. 2018 Aug;45(8):1173-1179. doi: 10.3899/jrheum.170326. Epub 2018 Jul 1.

4.

Trajectories of pain severity in juvenile idiopathic arthritis: results from the Research in Arthritis in Canadian Children Emphasizing Outcomes cohort.

Shiff NJ, Tupper S, Oen K, Guzman J, Lim H, Lee CH, Bryce R, Huber AM, Boire G, Dancey P, Feldman B, Laxer R, Miettunen P, Schmeling H, Watanabe Duffy K, Levy DM, Turvey S, Bolaria R, Bruns A, Cabral DA, Campillo S, Chédeville G, Feldman DE, Haddad E, Houghton K, Johnson N, Jurencak R, Lang B, Larche M, Morishita K, Ramsey S, Roth J, Schneider R, Scuccimarri R, Spiegel L, Stringer E, Tse SM, Yeung R, Duffy CM, Tucker LB.

Pain. 2018 Jan;159(1):57-66. doi: 10.1097/j.pain.0000000000001064.

PMID:
28937578
5.

Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort.

Guzman J, Kerr T, Ward LM, Ma J, Oen K, Rosenberg AM, Feldman BM, Boire G, Houghton K, Dancey P, Scuccimarri R, Bruns A, Huber AM, Watanabe Duffy K, Shiff NJ, Berard RA, Levy DM, Stringer E, Morishita K, Johnson N, Cabral DA, Larché M, Petty RE, Laxer RM, Silverman E, Miettunen P, Chetaille AL, Haddad E, Spiegel L, Turvey SE, Schmeling H, Lang B, Ellsworth J, Ramsey SE, Roth J, Campillo S, Benseler S, Chédeville G, Schneider R, Tse SML, Bolaria R, Gross K, Feldman D, Cameron B, Jurencak R, Dorval J, LeBlanc C, St Cyr C, Gibbon M, Yeung RSM, Duffy CM, Tucker LB.

Pediatr Rheumatol Online J. 2017 Aug 22;15(1):68. doi: 10.1186/s12969-017-0196-7.

6.

Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America.

Spencer CH, Rouster-Stevens K, Gewanter H, Syverson G, Modica R, Schmidt K, Emery H, Wallace C, Grevich S, Nanda K, Zhao YD, Shenoi S, Tarvin S, Hong S, Lindsley C, Weiss JE, Passo M, Ede K, Brown A, Ardalan K, Bernal W, Stoll ML, Lang B, Carrasco R, Agaiar C, Feller L, Bukulmez H, Vehe R, Kim H, Schmeling H, Gerstbacher D, Hoeltzel M, Eberhard B, Sundel R, Kim S, Huber AM, Patwardhan A; Pediatric Rheumatologist Collaborators.

Pediatr Rheumatol Online J. 2017 Jun 13;15(1):50. doi: 10.1186/s12969-017-0174-0.

7.

Health-Related Quality of Life in an Inception Cohort of Children With Juvenile Idiopathic Arthritis: A Longitudinal Analysis.

Oen K, Guzman J, Dufault B, Tucker LB, Shiff NJ, Duffy KW, Lee JJY, Feldman BM, Berard RA, Dancey P, Huber AM, Scuccimarri R, Cabral DA, Morishita KA, Ramsey SE, Rosenberg AM, Boire G, Benseler SM, Lang B, Houghton K, Miettunen PM, Chédeville G, Levy DM, Bruns A, Schmeling H, Haddad E, Yeung RSM, Duffy CM; the Research in Arthritis in Canadian Children emphasizing Outcomes (ReACCh-Out) investigators.

Arthritis Care Res (Hoboken). 2018 Jan;70(1):134-144. doi: 10.1002/acr.23236. Epub 2017 Dec 6.

8.

Erupted frothy xenoliths may explain lack of country-rock fragments in plutons.

Burchardt S, Troll VR, Schmeling H, Koyi H, Blythe L.

Sci Rep. 2016 Nov 2;6:34566. doi: 10.1038/srep34566.

9.

Management of Juvenile Idiopathic Arthritis 2015: A Position Statement from the Pediatric Committee of the Canadian Rheumatology Association.

Cellucci T, Guzman J, Petty RE, Batthish M, Benseler SM, Ellsworth JE, Houghton KM, LeBLANC CM, Huber AM, Luca N, Schmeling H, Shiff NJ, Soon GS, Tse SM; Pediatric Committee of the Canadian Rheumatology Association.

J Rheumatol. 2016 Oct;43(10):1773-1776. Review. No abstract available.

PMID:
27698103
10.

Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study.

Musset L, Allenbach Y, Benveniste O, Boyer O, Bossuyt X, Bentow C, Phillips J, Mammen A, Van Damme P, Westhovens R, Ghirardello A, Doria A, Choi MY, Fritzler MJ, Schmeling H, Muro Y, García-De La Torre I, Ortiz-Villalvazo MA, Bizzaro N, Infantino M, Imbastaro T, Peng Q, Wang G, Vencovský J, Klein M, Krystufkova O, Franceschini F, Fredi M, Hue S, Belmondo T, Danko K, Mahler M.

Autoimmun Rev. 2016 Oct;15(10):983-93. doi: 10.1016/j.autrev.2016.07.023. Epub 2016 Aug 1. Review.

PMID:
27491568
11.

Development of System-level Performance Measures for Evaluation of Models of Care for Inflammatory Arthritis in Canada.

Barber CE, Marshall DA, Mosher DP, Akhavan P, Tucker L, Houghton K, Batthish M, Levy DM, Schmeling H, Ellsworth J, Tibollo H, Grant S, Khodyakov D, Lacaille D; Arthritis Alliance of Canada Performance Measurement Development Panel.

J Rheumatol. 2016 Mar;43(3):530-40. doi: 10.3899/jrheum.150839. Epub 2016 Jan 15.

12.

Autoantibodies to Dense Fine Speckles in Pediatric Diseases and Controls.

Schmeling H, Mahler M, Levy DM, Moore K, Stevens AM, Wick J, McMillan JD, Horneff G, Assassi S, Charles J, Salazar G, Mayes MD, Silverman ED, Klien-Gitelman M, Lee T, Brunner HI, Reed AM, Fritzler MJ.

J Rheumatol. 2015 Dec;42(12):2419-26. doi: 10.3899/jrheum.150567. Epub 2015 Oct 15.

PMID:
26472409
13.

The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort.

Guzman J, Oen K, Huber AM, Watanabe Duffy K, Boire G, Shiff N, Berard RA, Levy DM, Stringer E, Scuccimarri R, Morishita K, Johnson N, Cabral DA, Rosenberg AM, Larché M, Dancey P, Petty RE, Laxer RM, Silverman E, Miettunen P, Chetaille AL, Haddad E, Houghton K, Spiegel L, Turvey SE, Schmeling H, Lang B, Ellsworth J, Ramsey SE, Bruns A, Roth J, Campillo S, Benseler S, Chédeville G, Schneider R, Tse SM, Bolaria R, Gross K, Feldman B, Feldman D, Cameron B, Jurencak R, Dorval J, LeBlanc C, St Cyr C, Gibbon M, Yeung RS, Duffy CM, Tucker LB; ReACCh-Out investigators.

Ann Rheum Dis. 2016 Jun;75(6):1092-8. doi: 10.1136/annrheumdis-2014-207164. Epub 2015 May 18.

PMID:
25985972
14.

Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?

Schmeling H, Horneff G, Benseler SM, Fritzler MJ.

Nat Rev Rheumatol. 2014 Nov;10(11):682-90. doi: 10.1038/nrrheum.2014.140. Epub 2014 Aug 12. Review.

PMID:
25112604
15.

Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.

Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G.

Arthritis Rheumatol. 2014 Sep;66(9):2580-9. doi: 10.1002/art.38741.

16.

The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort.

Guzman J, Oen K, Tucker LB, Huber AM, Shiff N, Boire G, Scuccimarri R, Berard R, Tse SM, Morishita K, Stringer E, Johnson N, Levy DM, Duffy KW, Cabral DA, Rosenberg AM, Larché M, Dancey P, Petty RE, Laxer RM, Silverman E, Miettunen P, Chetaille AL, Haddad E, Houghton K, Spiegel L, Turvey SE, Schmeling H, Lang B, Ellsworth J, Ramsey S, Bruns A, Campillo S, Benseler S, Chédeville G, Schneider R, Yeung R, Duffy CM; ReACCh-Out investigators.

Ann Rheum Dis. 2015 Oct;74(10):1854-60. doi: 10.1136/annrheumdis-2014-205372. Epub 2014 May 19.

PMID:
24842571
17.

Purpura, petechiae, and bullae as first signs of juvenile granulomatosis with polyangiitis.

Rawn S, Miettunen P, Brown HA, Schmeling H.

Eur J Pediatr. 2014 Dec;173(12):1685-9. doi: 10.1007/s00431-014-2298-2. Epub 2014 Mar 28.

PMID:
24677133
18.

Clinical characteristics of children with juvenile dermatomyositis: the Childhood Arthritis and Rheumatology Research Alliance Registry.

Robinson AB, Hoeltzel MF, Wahezi DM, Becker ML, Kessler EA, Schmeling H, Carrasco R, Huber AM, Feldman BM, Reed AM; Juvenile Myositis CARRA Subgroup, for the CARRA Registry Investigators.

Arthritis Care Res (Hoboken). 2014 Mar;66(3):404-10. doi: 10.1002/acr.22142.

19.

Inflammatory biomarkers of pediatric focal cerebral arteriopathy.

Mineyko A, Narendran A, Fritzler ML, Wei XC, Schmeling H, Kirton A.

Neurology. 2012 Sep 25;79(13):1406-8. Epub 2012 Aug 22. No abstract available.

PMID:
22914842
20.

Access to biologic therapies in Canada for children with juvenile idiopathic arthritis.

Leblanc CM, Lang B, Bencivenga A, Chetaille AL, Dancey P, Dent P, Miettunen P, Oen K, Rosenberg A, Roth J, Scuccimarri R, Tse SM, Benseler S, Cabral DA, Campillo S, Chédeville G, Duffy CM, Duffy KW, Haddad E, Huber AM, Laxer R, Levy D, Johnson N, Ramsey S, Shiff N, Schmeling H, Schneider R, Stringer E, Yeung RS, Tucker LB.

J Rheumatol. 2012 Sep;39(9):1875-9. doi: 10.3899/jrheum.120089. Epub 2012 Aug 1.

PMID:
22859344
21.

Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference.

Huber AM, Robinson AB, Reed AM, Abramson L, Bout-Tabaku S, Carrasco R, Curran M, Feldman BM, Gewanter H, Griffin T, Haines K, Hoeltzel MF, Isgro J, Kahn P, Lang B, Lawler P, Shaham B, Schmeling H, Scuccimarri R, Shishov M, Stringer E, Wohrley J, Ilowite NT, Wallace C; Juvenile Dermatomyositis Subcommittee of the Childhood Arthritis and Rheumatology Research Alliance.

Arthritis Care Res (Hoboken). 2012 Apr;64(4):546-53. doi: 10.1002/acr.20695.

22.

Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis.

Schmeling H, Stephens S, Goia C, Manlhiot C, Schneider R, Luthra S, Stringer E, Feldman BM.

Rheumatology (Oxford). 2011 May;50(5):885-93. doi: 10.1093/rheumatology/keq407. Epub 2010 Dec 13.

PMID:
21156669
23.

Response times follow lognormal or gamma distribution in arthritis patients.

Abrahamyan L, Beyene J, Feng J, Chon Y, Willan AR, Schmeling H, Horneff G, Keystone EC, Feldman BM.

J Clin Epidemiol. 2010 Dec;63(12):1363-9. doi: 10.1016/j.jclinepi.2009.11.019.

PMID:
20430577
24.

Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.

Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, Schmeling H; German and Austrian Paediatric Rheumatology Collaborative Study Group.

Ann Rheum Dis. 2009 Apr;68(4):519-25. doi: 10.1136/ard.2007.087593. Epub 2008 Apr 15.

PMID:
18413440
25.

Tumour necrosis factor alpha promoter polymorphisms and etanercept therapy in juvenile idiopathic arthritis.

Schmeling H, Horneff G.

Rheumatol Int. 2007 Feb;27(4):383-6. Epub 2006 Sep 2.

PMID:
16951943
26.

Tumor necrosis factor alpha promoter polymorphisms in patients with juvenile idiopathic arthritis.

Schmeling H, Wagner U, Peterson A, Horneff G.

Clin Exp Rheumatol. 2006 Jan-Feb;24(1):103-8.

PMID:
16539828
27.

Pneumococcal sepsis after autosplenectomy in a girl with systemic lupus erythematosus.

Hühn R, Schmeling H, Kunze C, Horneff G.

Rheumatology (Oxford). 2005 Dec;44(12):1586-8. Epub 2005 Oct 11. No abstract available.

PMID:
16219642
28.
29.

Etanercept and uveitis in patients with juvenile idiopathic arthritis.

Schmeling H, Horneff G.

Rheumatology (Oxford). 2005 Aug;44(8):1008-11. Epub 2005 Apr 26.

PMID:
15855187
30.

The German etanercept registry for treatment of juvenile idiopathic arthritis.

Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, Hospach T, Huppertz HI, Keitzer R, Küster RM, Michels H, Moebius D, Rogalski B, Thon A; Paediatric Rheumatology Collaborative Group.

Ann Rheum Dis. 2004 Dec;63(12):1638-44. Epub 2004 Apr 28. Review.

31.

Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations.

Foell D, Wittkowski H, Hammerschmidt I, Wulffraat N, Schmeling H, Frosch M, Horneff G, Kuis W, Sorg C, Roth J.

Arthritis Rheum. 2004 Apr;50(4):1286-95.

32.

Growth reconstitution in juvenile idiopathic arthritis treated with etanercept.

Schmeling H, Seliger E, Horneff G.

Clin Exp Rheumatol. 2003 Nov-Dec;21(6):779-84.

PMID:
14740460
33.

Infliximab in two patients with juvenile ankylosing spondylitis.

Schmeling H, Horneff G.

Rheumatol Int. 2004 May;24(3):173-6. Epub 2003 Nov 29.

PMID:
14648110
34.

Pulmonary function in children with juvenile idiopathic arthritis and effects of methotrexate therapy.

Schmeling H, Stephan V, Burdach S, Horneff G.

Z Rheumatol. 2002 Apr;61(2):168-72.

PMID:
12056294
35.

[Prader-Labhart-Willi syndrome in infants].

Schmeling H, Gillessen-Kaesbach G, Schulte-Mattler U, Burdach S, Horneff G.

Klin Padiatr. 2002 Mar-Apr;214(2):51-3. German.

PMID:
11972309
36.

A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study.

Schmeling H, Mathony K, John V, Keysser G, Burdach S, Horneff G.

Ann Rheum Dis. 2001 Apr;60(4):410-2.

37.

Quantitative assessment of immediate cutaneous hypersensitivity in a model of genetic predisposition to atopy.

Daser A, Bätjer N, Kölsch U, Kötz K, Schmeling H, Schou C, Renz H.

Int Arch Allergy Immunol. 1998 Dec;117(4):239-43.

PMID:
10048895

Supplemental Content

Loading ...
Support Center